Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

This study could potentially impact the stock performance of Regeneron Pharmaceuticals and Sanofi, as positive results may enhance investor sentiment and market valuation. The study’s focus on COPD, a ...

Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company reported strong second-quarter financial results that significantly surpassed analyst ...

Sales of the anti-inflammatory drug rose 22% to $4.34 billion, compared with an estimate of $4.14 billion. The Tarrytown, New ...

Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Against steep odds and well-established paradigms, these four companies have successfully been commercializing their products ...

SNY misses Q2 earnings and sales estimates but lifts 2025 sales outlook on strong Dupixent and vaccine momentum.

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

The White House announced on Thursday that President Trump sent 17 major pharmaceutical companies letters delineating the ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...